BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31820579)

  • 1. How I investigate acute myeloid leukemia.
    Narayanan D; Weinberg OK
    Int J Lab Hematol; 2020 Feb; 42(1):3-15. PubMed ID: 31820579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing.
    Mack EKM; Marquardt A; Langer D; Ross P; Ultsch A; Kiehl MG; Mack HID; Haferlach T; Neubauer A; Brendel C
    Haematologica; 2019 Feb; 104(2):277-287. PubMed ID: 30190345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Malfeasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia.
    King RL; Bagg A
    Methods Mol Biol; 2017; 1633():1-17. PubMed ID: 28735477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?
    Madanat YF; Kalaycio ME; Nazha A
    Acta Med Acad; 2019 Apr; 48(1):35-44. PubMed ID: 31264431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Cytogenetic Abnormalities in Acute Myeloid Leukemia.
    Yang JJ; Park TS; Wan TS
    Methods Mol Biol; 2017; 1541():223-245. PubMed ID: 27910027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
    Eisfeld AK; Mrózek K; Kohlschmidt J; Nicolet D; Orwick S; Walker CJ; Kroll KW; Blachly JS; Carroll AJ; Kolitz JE; Powell BL; Wang ES; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Leukemia; 2017 Oct; 31(10):2211-2218. PubMed ID: 28321123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular cytogenetics in acute myeloid leukemia in adult patients: practical implications.
    Mrózek K
    Pol Arch Intern Med; 2022 Aug; 132(7-8):. PubMed ID: 35848612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.
    Khalidi HS; Medeiros LJ; Chang KL; Brynes RK; Slovak ML; Arber DA
    Am J Clin Pathol; 1998 Feb; 109(2):211-20. PubMed ID: 9583894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia.
    Aypar U; Smoley SA; Pitel BA; Pearce KE; Zenka RM; Vasmatzis G; Johnson SH; Smadbeck JB; Peterson JF; Geiersbach KB; Van Dyke DL; Thorland EC; Jenkins RB; Ketterling RP; Greipp PT; Kearney HM; Hoppman NL; Baughn LB
    Eur J Haematol; 2019 Jan; 102(1):87-96. PubMed ID: 30270457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphologic and Molecular Characteristics of De Novo AML With
    Hidalgo-López JE; Kanagal-Shamanna R; Medeiros LJ; Estrov Z; Yin CC; Verstovsek S; Konoplev S; Jorgensen JL; Mohammad MM; Miranda RN; Zhao C; Lee J; Zuo Z; Bueso-Ramos CE
    J Natl Compr Canc Netw; 2017 Jun; 15(6):790-796. PubMed ID: 28596259
    [No Abstract]   [Full Text] [Related]  

  • 12. Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications.
    Rosli AA; Azlan A; Rajasegaran Y; Mot YY; Heidenreich O; Yusoff NM; Moses EJ
    Clin Exp Med; 2023 Aug; 23(4):1137-1159. PubMed ID: 36229751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [AML treatment strategy based on cytogenetic abnormalities and somatic mutations].
    Imai Y
    Rinsho Ketsueki; 2015 Oct; 56(10):1932-41. PubMed ID: 26458431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
    Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
    Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China.
    Zheng J; Wang X; Hu Y; Yang J; Liu J; He Y; Gong Q; Yao J; Li X; Du W; Huang S
    Cytometry B Clin Cytom; 2008 Jan; 74(1):25-9. PubMed ID: 18061959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis.
    Fernandez C; Santos-Silva MC; López A; Matarraz S; Jara-Acevedo M; Ciudad J; Gutierrez ML; Sánchez ML; Salvador-Osuna C; Berruezo MJ; Díaz-Arias JÁ; Palomo-Hernández AM; Colado E; González N; Gallardo D; Asensio A; García-Sánchez R; Saldaña R; Cerveró C; Carboné-Bañeres A; Gutierrez O; Orfao A
    Leukemia; 2013 Nov; 27(11):2149-56. PubMed ID: 23579575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.